Award type :
Product Development Award
Product Development Award
Product type :
Therapeutics
Therapeutics
Award year :
2022
2022
Project start date :
09 / 30 / 2022
09 / 30 / 2022
Project end date :
03 / 31 / 2025
03 / 31 / 2025
Project duration (months) :
24
24
Development stage :
Phase 2, Phase 3
Phase 2, Phase 3
Target disease :
Malaria
Malaria
Region served :
World
World
Recipient organization / Country of funding recipient organization :
Merck KGaA / Germany
Merck KGaA / Germany
Collaborator(s) / Country :
Shin Poong Pharm. Co., Ltd. / Republic of Korea
Shin Poong Pharm. Co., Ltd. / Republic of Korea
Funding amount(KRW) :
4,410,509,932
4,410,509,932
The aim of this project is to develop the prevention indication of a monthly fixed-dose combination of M5717 and pyronaridine against malaria. Pyronaridine is currently registered as a malaria treatment in over 25 countries, while the antimalarial activity of M5717 has been demonstrated in FIH and challenge studies. The combination leverages complementary modes of action in blood stage parasite killing. The project activities would include a preclinical toxicology study, Phase IIa study of singledose combination and Phase IIb study to evaluate repeat dosing (animals) and inclusion of women of childbearing potential. The M5717+pyronaridine combination is simultaneously being evaluated for its therapeutic indication through separate funding.